Resources

The Digital Innovation in Pandemic Control (DIPC) project, launched in November 2022, is a collaborative initiative led by GIZ and Digital Square at PATH to strengthen immunization systems in Ghana, Malawi, and Tanzania. In response to the fragmentation and lack of interoperability exposed during the COVID‑19 pandemic, DIPC works closely with country health ministries to select, localize, and implement digital public health tools—such as Electronic Immunization Registries and WHO SMART-based Digital Adaptation Kits—to build scalable, interoperable, and locally sustainable immunization platforms. Through end-to-end ecosystem mapping, system enhancement, and capacity building, the project aims to create resilient, digitally enabled immunization workflows that can support both routine vaccination and future pandemic preparedness across participating countries by 2025.

As part of the Strengthening Vaccine-Preventable Disease Surveillance System Assessment, 23 countries responded to the landscape survey, which included 86 questions, including a mix of yes or no and multiple-choice questions, making them primarily quantitative. A smaller number of open-ended questions captured more qualitative or contextual information. Survey responses were mapped to indicators within specific sub-domains of a maturity model, with scores calculated for each sub-domain. These were then averaged to generate an overall maturity score for each of the eight main domains.

Supporting governments and partners across Africa to enhance surveillance systems for vaccine-preventable diseases. Through a regional assessment initiative, we evaluated digital readiness, system capacity, and data quality to identify opportunities to strengthen surveillance for better disease detection, reporting, and response.

Country- and Community-Led Scale-Up of Accessible, Integrated, and Family-Centered EVT Plus Services for a Healthy Start (SAFEStart+)While childhood survival rates have significantly improved in the past decade, every year, approximately five million children die before their fifth birthday—almost half are newborns in their first month of life. Vertical transmission of HIV, syphilis, hepatitis B, and Chagas disease is a leading cause of preventable stillbirth and child mortality. Timely diagnosis and treatment of these infections are critical to protect the health and well-being of women, infants, and young children.Through partnership and funding from Unitaid, PATH and the project’s co-leads, the International Community of Women living with HIV Eastern Africa and the World Hepatitis Alliance, are leading a four-year project designed for maximum reach and impact: SAFEStart+. This project is accelerating demand and adoption of evidence-based approaches and integrated delivery strategies to eliminate vertical transmission of HIV, syphilis, hepatitis B, and Chagas disease.SAFEStart+ is supporting countries and communities to design and scale integrated, people-centered services that meet local needs. This includes expanding access to new diagnostics that can detect multiple infections with a single test and reinforcing antenatal care services to deliver preventive treatment when it matters most.

This is a simple, Excel-based tool for assessing and comparing costs of rotavirus vaccination programs with each rotavirus vaccine product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different rotavirus vaccines, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting a rotavirus vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.